Advertisement

Disorders of Carbohydrate Metabolism and Glucose Transport

  • René SanterEmail author
  • Joerg Klepper
  • G. Peter A. Smit
Chapter

Abstract

Carbohydrates are one of the most important sources of energy in the human organism. Within the body, glucose is the most abundant monosaccharide which can be stored as glycogen, a branched polymer, in liver and muscle. Inborn errors of metabolism may affect the uptake, distribution and reabsorption of monosaccharides in different organs, a process which is meticulously regulated by a system of transporter proteins. Congenital disorders may impair the conversion of other monosaccharides (fructose, galactose) into glucose. They can further affect glycogen formation, glycogen breakdown (glycogenolysis), glucose metabolism to acetyl-CoA (glycolysis) and de novo synthesis of glucose from glucoplastic amino acids or from lactate (gluconeogenesis).

Glucose transport disorders present with a very variable clinical picture depending on which of the organ- and substrate-specific transporters are affected. This group of disorders includes intestinal glucose-galactose malabsorption, renal glucosuria, glucose transporter-1 deficiency of the blood-brain barrier and Fanconi-Bickel syndrome (a disease with hepatic glycogen storage and massive renal tubular malabsorption of glucose and other substances).

Disorders of fructose and galactose metabolism affect different organs because of the accumulation of toxic intermediates. After these monosaccharides have been introduced with the diet, symptoms secondary to impaired liver function are frequently the first signs.

Glycogen storage diseases can be divided into those mainly presenting with hepatic manifestations (hepatomegaly, hypoglycaemia) and those with muscular presentations (exertion intolerance, rhabdomyolysis). Some show a combination of these symptoms, cardiomyopathy may be an additional feature, and further accompanying symptoms, e.g. haemolytic anaemia, may be observed depending on the tissue distribution of the affected protein.

Management of most carbohydrate disorders requires symptomatic measures, supportive care and a multidisciplinary approach. In some conditions, dietetic treatment is possible which may have its basis in an exclusion of certain monosaccharides. A ketogenic diet supplying non-carbohydrate energy sources may have dramatic effects in glucose transporter-1 deficiency, and frequent meals or the administration of slowly absorbed carbohydrates are successful means to avoid hypoglycaemia in disorders with impaired endogenous glucose production. Outcome, however, is very variable and mainly depends on the underlying type of disorder. A causal treatment is not available for most types of carbohydrate disorders. Enzyme replacement therapy (with as yet unsatisfactory results) is only available for lysosomal α-glucosidase deficiency (GSD-IIa). In some patients with severe types of disorders or an unfavourable course, organ transplantation (liver, kidney, heart) is the only option for long-term survival.

Keywords

Enzyme Replacement Therapy Ketogenic Diet Glycogen Storage Disease Amniotic Fluid Cell Ethinyl Oestradiol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Lee YC, Huang HY, Chang CJ, Cheng CH, Chen YT (2010) Mitochondrial GLUT10 facilitates dehydroascorbic acid import and protects cells against oxidative stress: mechanistic insight into arterial tortuosity syndrome. Hum Mol Genet 19:3721–3733PubMedCrossRefGoogle Scholar
  2. Pérez B, Medrano C, Ecay MJ et al (2013) A novel congenital disorder of glycosylation type without central nervous system involvement caused by mutations in the phosphoglucomutase 1 gene. J Inherit Metab Dis 36:535–542PubMedCrossRefGoogle Scholar
  3. Santer R, Klepper J (2012) Disorders of glucose transport. In: Saudubray JM, van den Berghe G, Walter JH (eds) Inborn metabolic diseases, 5th edn. Springer, Heidelberg, pp 175–183CrossRefGoogle Scholar

Further Reading

  1. Berrry GT, Walter JH (2012) Disorders of galactose metabolism. In: Fernandes J, Saudubray JM, van den Berghe G, Walter JH (eds) Inborn metabolic diseases, 5th edn. Springer, Heidelberg, pp 141–150CrossRefGoogle Scholar
  2. Bosch AM (2011) Classic galactosemia: dietary dilemmas. J Inherit Metab Dis 34:257–260PubMedCentralPubMedCrossRefGoogle Scholar
  3. Bosch AM, Grootenhuis MA, Bakker HD, Heijmans HS, Wijburg FA, Last BF (2004) Living with classical galactosemia: health-related quality of life consequences. Pediatrics 113:e423–e428PubMedCrossRefGoogle Scholar
  4. Bouteldja N, Timson DJ (2010) The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis 33:105–112PubMedCrossRefGoogle Scholar
  5. Chen YT (2001) Glycogen storage diseases. In: Scriver CR, Beaudet A, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. New York, McGraw-Hill, pp 1521–1551Google Scholar
  6. Chou JY, Raben N (2002) Glycogen storage diseases (GSDs). Curr Mol Med 2:101–227CrossRefGoogle Scholar
  7. Chou JY, Jun HS, Mansfield BC (2010) Neutropenia in type Ib glycogen storage disease. Curr Opin Hematol 17:36–42PubMedCentralPubMedCrossRefGoogle Scholar
  8. Däublin G, Schwahn B, Wendel U (2002) Type I glycogen storage disease: favourable outcome on a strict management regimen avoiding increased lactate production during childhood and adolescence. Eur J Pediatr 161:S40–S45PubMedCrossRefGoogle Scholar
  9. Davis MK, Weinstein DA (2008) Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant 12:137–145PubMedCrossRefGoogle Scholar
  10. DiMauro S, Spiegel R (2011) Progress and problems in muscle glycogenoses. Acta Myol 30:96–102PubMedCentralPubMedGoogle Scholar
  11. Holton JB, Walter JH, Tyfield LA (2001) Galactosemia. In: Sly WS, Valle D, Scriver CR, Beaudet al (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1553–1587Google Scholar
  12. Huidekoper HH, Visser G, Ackermans MT, Sauerwein HP, Wijburg FA (2010) A potential role for muscle in glucose homeostasis: in vivo kinetic studies in glycogen storage disease type 1a and fructose-1,6-bisphosphatase deficiency. J Inherit Metab Dis 33:25–31PubMedCentralPubMedCrossRefGoogle Scholar
  13. Jumbo-Lucioni PP, Garber K, Kiel J et al (2012) Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes. J Inherit Metab Dis 35:1037–1049PubMedCentralPubMedCrossRefGoogle Scholar
  14. Kishnani P, Chen YT (2011) Disorders of glycogen metabolism. In: Rudolph CD, Rudolph AM, Lister GE et al (eds) Rudolph’s pediatrics, 22nd edn. McGraw Hill, New York, pp 599–607Google Scholar
  15. Kishnani PS, Corzo D, Leslie ND et al (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66:329–635PubMedCentralPubMedCrossRefGoogle Scholar
  16. Laforêt P, Weinstein D, Smit GPA (2011) The glycogen storage diseases and related disorders. In: Saudubray JM, van den Berghe G, Walter JH (eds) Inborn metabolic diseases, 5th edn. Springer, Heidelberg, pp 115–139Google Scholar
  17. Leen WG, Klepper J, Verbeek MM et al (2010) Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 133:655–670PubMedCrossRefGoogle Scholar
  18. Maheshwari A, Rankin R, Segev DL, Thuluvath PJ (2012) Outcomes of liver transplantation for glycogen storage disease: a matched-control study and a review of literature. Clin Transplant 26:432–436PubMedCrossRefGoogle Scholar
  19. Martens DH, Rake JP, Navis G, Fidler V, van Dael CM, Smit GP (2009) Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition. Clin J Am Soc Nephrol 4:1741–1746PubMedCentralPubMedCrossRefGoogle Scholar
  20. Rake JP, Visser G, Labrune P et al (2002) Guidelines for management of glycogen storage disease type I – European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161:S112–S119PubMedCrossRefGoogle Scholar
  21. Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133–141PubMedCrossRefGoogle Scholar
  22. Santer R, Klepper J (2012) Disorders of glucose transport. In: Fernandes J, Saudubray JM, van den Berghe G, Walter JH (eds) Inborn metabolic diseases, 4th edn. Springer, Heidelberg, pp 141–150Google Scholar
  23. Santer R, Ullrich K (2004) Cardiac involvement of glycogen storage diseases. In: Böhles H, Sewell AC (eds) Metabolic cardiomyopathy. Medpharm, Stuttgart, pp 47–65Google Scholar
  24. Santer R, Steinmann B, Schaub J (2002) Fanconi-Bickel syndrome – a congenital defect of facilitative glucose transport. Curr Mol Med 2:213–222PubMedCrossRefGoogle Scholar
  25. Santer R, Rischewski J, von Weihe M et al (2005) The spectrum of aldolase B (ALDOB) mutations and the prevalence of hereditary fructose intolerance in Central Europe. Hum Mutat 25:594PubMedCrossRefGoogle Scholar
  26. Steinmann B, Santer R (2012) Disorders of fructose metabolism. In: Fernandes J, Saudubray JM, van den Berghe G, Walter JH (eds) Inborn metabolic diseases, 4th edn. Springer, Heidelberg, pp 101–112Google Scholar
  27. Waisbren SE, Potter NL, Gordon CM et al (2012) The adult galactosemic phenotype. J Inherit Metab Dis 35:279–286PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • René Santer
    • 1
    Email author
  • Joerg Klepper
    • 2
  • G. Peter A. Smit
    • 3
  1. 1.Department of PediatricsUniversity Medical Center Hamburg EppendorfHamburgGermany
  2. 2.KinderklinikKlinikum AschaffenburgAschaffenburgGermany
  3. 3.Department of Metabolic DiseasesBeatrix Children’s HospitalGroningenThe Netherlands

Personalised recommendations